Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeyoND long-term safety study of subcutaneous ND0612 in advanced Parkinson's disease
2015-005814-31Phase 2Active
- Sponsor
- NeuroDerm Ltd.
- Start
- May 2016
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ND0612 in Parkinson's disease (PD), sponsored by NeuroDerm Ltd. Primary endpoints: Long-term safety and tolerability of continuous subcutaneous ND0612 and Adverse events of special interest. Started May 2016; status: active.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2015-005814-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005814-31.